Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-03

AUTHORS

Paul Tappenden, Emma Simpson, Jean Hamilton, Daniel Pollard, Mark Clowes, Eva Kaltenthaler, David Meiklejohn, Nick Morley

ABSTRACT

As part of its Single Technology Appraisal process, the UK National Institute for Health and Care Excellence (NICE) invited the manufacturer of ibrutinib (Janssen) to submit evidence on the clinical effectiveness and cost effectiveness of ibrutinib for the treatment of relapsed or refractory (R/R) mantle cell lymphoma (MCL). The School of Health and Related Research Technology Assessment Group at the University of Sheffield was commissioned to act as the independent Evidence Review Group (ERG). The ERG produced a critical review of the evidence contained within the company's submission to NICE. The clinical effectiveness evidence for ibrutinib included one randomised controlled trial comparing ibrutinib and temsirolimus and two single-arm studies. The company's indirect comparison of ibrutinib versus rituximab plus chemotherapy (R-chemo) produced a hazard ratio (HR) for progression-free survival (PFS) of 0.28. The ERG's random effects network meta-analysis (NMA) indicated that the treatment effect on PFS was highly uncertain (HR 0.27; 95% credible interval (CrI) 0.06-1.26). The company's Markov model assessed the cost effectiveness of ibrutinib versus R-chemo for the treatment of R/R MCL from the perspective of the National Health Service (NHS) and Personal Social Services over a lifetime horizon. Based on a re-run of the company's model by the ERG, the incremental cost-effectiveness ratio (ICER) for ibrutinib versus R-chemo [including the company's original patient access scheme (PAS)] was expected to be £76,014 per quality-adjusted life-year (QALY) gained. The ERG had several concerns regarding the company's model structure and the evidence used to inform its parameters. The ERG's preferred analysis, which used the ERG's NMA and the observed Kaplan-Meier curve for time to ibrutinib discontinuation and excluded long-term disutilities for R-chemo, produced ICERs of £63,340 per QALY gained for the overall R/R MCL population and of £44,711 per QALY gained for patients with one prior treatment. Following an updated PAS and consideration of evidence from a later data-cut of the RAY trial, the appraisal committee concluded that the most plausible ICER for the one prior treatment subgroup was likely to be lower than the company's estimate of £49,848 per QALY gained. The company's ICER for the overall R/R MCL population was higher, at £62,650 per QALY gained. The committee recommended ibrutinib as an option for treating R/R MCL in adults only if they have received only one previous line of therapy and the company provides ibrutinib with the discount agreed in the commercial access agreement with NHS England. More... »

PAGES

1-11

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40273-018-0713-7

DOI

http://dx.doi.org/10.1007/s40273-018-0713-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1107187582

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30246228


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Sheffield", 
          "id": "https://www.grid.ac/institutes/grid.11835.3e", 
          "name": [
            "ScHARR, University of Sheffield, Regent Court, 30 Regent Street, S1 4DA, Sheffield, England, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tappenden", 
        "givenName": "Paul", 
        "id": "sg:person.0670022306.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0670022306.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Sheffield", 
          "id": "https://www.grid.ac/institutes/grid.11835.3e", 
          "name": [
            "ScHARR, University of Sheffield, Regent Court, 30 Regent Street, S1 4DA, Sheffield, England, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Simpson", 
        "givenName": "Emma", 
        "id": "sg:person.0730713040.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0730713040.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Sheffield", 
          "id": "https://www.grid.ac/institutes/grid.11835.3e", 
          "name": [
            "ScHARR, University of Sheffield, Regent Court, 30 Regent Street, S1 4DA, Sheffield, England, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hamilton", 
        "givenName": "Jean", 
        "id": "sg:person.013633412165.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013633412165.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Sheffield", 
          "id": "https://www.grid.ac/institutes/grid.11835.3e", 
          "name": [
            "ScHARR, University of Sheffield, Regent Court, 30 Regent Street, S1 4DA, Sheffield, England, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pollard", 
        "givenName": "Daniel", 
        "id": "sg:person.0614330503.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0614330503.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Sheffield", 
          "id": "https://www.grid.ac/institutes/grid.11835.3e", 
          "name": [
            "ScHARR, University of Sheffield, Regent Court, 30 Regent Street, S1 4DA, Sheffield, England, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Clowes", 
        "givenName": "Mark", 
        "id": "sg:person.015226353165.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015226353165.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Sheffield", 
          "id": "https://www.grid.ac/institutes/grid.11835.3e", 
          "name": [
            "ScHARR, University of Sheffield, Regent Court, 30 Regent Street, S1 4DA, Sheffield, England, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kaltenthaler", 
        "givenName": "Eva", 
        "id": "sg:person.0666733253.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0666733253.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ninewells Hospital", 
          "id": "https://www.grid.ac/institutes/grid.416266.1", 
          "name": [
            "Department of Haematology, Ninewells Hospital, Dundee, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Meiklejohn", 
        "givenName": "David", 
        "id": "sg:person.01160346603.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01160346603.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sheffield Teaching Hospitals NHS Foundation Trust", 
          "id": "https://www.grid.ac/institutes/grid.31410.37", 
          "name": [
            "Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Morley", 
        "givenName": "Nick", 
        "id": "sg:person.014071540030.75", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014071540030.75"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1111/bjh.12046", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001169896"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2004-04-1323", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019072310"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jval.2013.03.690", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021079104"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1098-3015(10)74336-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023922575"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.20.7977", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025441690"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jval.2014.08.2196", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027439758"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1306220", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035996659"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1306220", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035996659"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mds643", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037425350"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(15)00667-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037749972"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-03", 
    "datePublishedReg": "2019-03-01", 
    "description": "As part of its Single Technology Appraisal process, the UK National Institute for Health and Care Excellence (NICE) invited the manufacturer of ibrutinib (Janssen) to submit evidence on the clinical effectiveness and cost effectiveness of ibrutinib for the treatment of relapsed or refractory (R/R) mantle cell lymphoma (MCL). The School of Health and Related Research Technology Assessment Group at the University of Sheffield was commissioned to act as the independent Evidence Review Group (ERG). The ERG produced a critical review of the evidence contained within the company's submission to NICE. The clinical effectiveness evidence for ibrutinib included one randomised controlled trial comparing ibrutinib and temsirolimus and two single-arm studies. The company's indirect comparison of ibrutinib versus rituximab plus chemotherapy (R-chemo) produced a hazard ratio (HR) for progression-free survival (PFS) of 0.28. The ERG's random effects network meta-analysis (NMA) indicated that the treatment effect on PFS was highly uncertain (HR 0.27; 95% credible interval (CrI) 0.06-1.26). The company's Markov model assessed the cost effectiveness of ibrutinib versus R-chemo for the treatment of R/R MCL from the perspective of the National Health Service (NHS) and Personal Social Services over a lifetime horizon. Based on a re-run of the company's model by the ERG, the incremental cost-effectiveness ratio (ICER) for ibrutinib versus R-chemo [including the company's original patient access scheme (PAS)] was expected to be \u00a376,014 per quality-adjusted life-year (QALY) gained. The ERG had several concerns regarding the company's model structure and the evidence used to inform its parameters. The ERG's preferred analysis, which used the ERG's NMA and the observed Kaplan-Meier curve for time to ibrutinib discontinuation and excluded long-term disutilities for R-chemo, produced ICERs of \u00a363,340 per QALY gained for the overall R/R MCL population and of \u00a344,711 per QALY gained for patients with one prior treatment. Following an updated PAS and consideration of evidence from a later data-cut of the RAY trial, the appraisal committee concluded that the most plausible ICER for the one prior treatment subgroup was likely to be lower than the company's estimate of \u00a349,848 per QALY gained. The company's ICER for the overall R/R MCL population was higher, at \u00a362,650 per QALY gained. The committee recommended ibrutinib as an option for treating R/R MCL in adults only if they have received only one previous line of therapy and the company provides ibrutinib with the discount agreed in the commercial access agreement with NHS England.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s40273-018-0713-7", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1102812", 
        "issn": [
          "1170-7690", 
          "1179-2027"
        ], 
        "name": "PharmacoEconomics", 
        "type": "Periodical"
      }
    ], 
    "name": "Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal", 
    "pagination": "1-11", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "2a6a7e2c566717a8298a281a262789859ffd795a376685ff8022ceadbf5d3cbb"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30246228"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9212404"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40273-018-0713-7"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1107187582"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40273-018-0713-7", 
      "https://app.dimensions.ai/details/publication/pub.1107187582"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T21:42", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8687_00000539.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs40273-018-0713-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40273-018-0713-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40273-018-0713-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40273-018-0713-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40273-018-0713-7'


 

This table displays all metadata directly associated to this object as RDF triples.

145 TRIPLES      21 PREDICATES      36 URIs      19 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40273-018-0713-7 schema:about anzsrc-for:11
2 anzsrc-for:1117
3 schema:author N811fa1e58f224534b52b851f810c6d11
4 schema:citation https://doi.org/10.1016/j.jval.2013.03.690
5 https://doi.org/10.1016/j.jval.2014.08.2196
6 https://doi.org/10.1016/s0140-6736(15)00667-4
7 https://doi.org/10.1016/s1098-3015(10)74336-9
8 https://doi.org/10.1056/nejmoa1306220
9 https://doi.org/10.1093/annonc/mds643
10 https://doi.org/10.1111/bjh.12046
11 https://doi.org/10.1182/blood-2004-04-1323
12 https://doi.org/10.1200/jco.2008.20.7977
13 schema:datePublished 2019-03
14 schema:datePublishedReg 2019-03-01
15 schema:description As part of its Single Technology Appraisal process, the UK National Institute for Health and Care Excellence (NICE) invited the manufacturer of ibrutinib (Janssen) to submit evidence on the clinical effectiveness and cost effectiveness of ibrutinib for the treatment of relapsed or refractory (R/R) mantle cell lymphoma (MCL). The School of Health and Related Research Technology Assessment Group at the University of Sheffield was commissioned to act as the independent Evidence Review Group (ERG). The ERG produced a critical review of the evidence contained within the company's submission to NICE. The clinical effectiveness evidence for ibrutinib included one randomised controlled trial comparing ibrutinib and temsirolimus and two single-arm studies. The company's indirect comparison of ibrutinib versus rituximab plus chemotherapy (R-chemo) produced a hazard ratio (HR) for progression-free survival (PFS) of 0.28. The ERG's random effects network meta-analysis (NMA) indicated that the treatment effect on PFS was highly uncertain (HR 0.27; 95% credible interval (CrI) 0.06-1.26). The company's Markov model assessed the cost effectiveness of ibrutinib versus R-chemo for the treatment of R/R MCL from the perspective of the National Health Service (NHS) and Personal Social Services over a lifetime horizon. Based on a re-run of the company's model by the ERG, the incremental cost-effectiveness ratio (ICER) for ibrutinib versus R-chemo [including the company's original patient access scheme (PAS)] was expected to be £76,014 per quality-adjusted life-year (QALY) gained. The ERG had several concerns regarding the company's model structure and the evidence used to inform its parameters. The ERG's preferred analysis, which used the ERG's NMA and the observed Kaplan-Meier curve for time to ibrutinib discontinuation and excluded long-term disutilities for R-chemo, produced ICERs of £63,340 per QALY gained for the overall R/R MCL population and of £44,711 per QALY gained for patients with one prior treatment. Following an updated PAS and consideration of evidence from a later data-cut of the RAY trial, the appraisal committee concluded that the most plausible ICER for the one prior treatment subgroup was likely to be lower than the company's estimate of £49,848 per QALY gained. The company's ICER for the overall R/R MCL population was higher, at £62,650 per QALY gained. The committee recommended ibrutinib as an option for treating R/R MCL in adults only if they have received only one previous line of therapy and the company provides ibrutinib with the discount agreed in the commercial access agreement with NHS England.
16 schema:genre research_article
17 schema:inLanguage en
18 schema:isAccessibleForFree false
19 schema:isPartOf sg:journal.1102812
20 schema:name Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
21 schema:pagination 1-11
22 schema:productId N87ee5357451d4f9ebc4e658072423049
23 N8a967be511c64ac0ab48cdbee16eb577
24 N9094cd9172b44a5c970949995fca4acb
25 Ncf986a5653a94c599ee54896aad3403d
26 Ndc29e15b20484a4dbfc82002b952a6af
27 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107187582
28 https://doi.org/10.1007/s40273-018-0713-7
29 schema:sdDatePublished 2019-04-10T21:42
30 schema:sdLicense https://scigraph.springernature.com/explorer/license/
31 schema:sdPublisher N5813c13e6ff94ac8b9d0dd935e27cac8
32 schema:url http://link.springer.com/10.1007%2Fs40273-018-0713-7
33 sgo:license sg:explorer/license/
34 sgo:sdDataset articles
35 rdf:type schema:ScholarlyArticle
36 N168488a8b500405fac8480098e781732 rdf:first sg:person.013633412165.54
37 rdf:rest Nff7099b094e945e4ad199949fe2a5c95
38 N5813c13e6ff94ac8b9d0dd935e27cac8 schema:name Springer Nature - SN SciGraph project
39 rdf:type schema:Organization
40 N6c57cd8f1a344a5cb4d02e6805be02de rdf:first sg:person.0730713040.61
41 rdf:rest N168488a8b500405fac8480098e781732
42 N811fa1e58f224534b52b851f810c6d11 rdf:first sg:person.0670022306.41
43 rdf:rest N6c57cd8f1a344a5cb4d02e6805be02de
44 N87ee5357451d4f9ebc4e658072423049 schema:name readcube_id
45 schema:value 2a6a7e2c566717a8298a281a262789859ffd795a376685ff8022ceadbf5d3cbb
46 rdf:type schema:PropertyValue
47 N8a967be511c64ac0ab48cdbee16eb577 schema:name dimensions_id
48 schema:value pub.1107187582
49 rdf:type schema:PropertyValue
50 N9094cd9172b44a5c970949995fca4acb schema:name pubmed_id
51 schema:value 30246228
52 rdf:type schema:PropertyValue
53 N98b5417c7ff045eda6fe5a467337a8be rdf:first sg:person.014071540030.75
54 rdf:rest rdf:nil
55 Na36d2bc907284dc4bdc7c9ebddd60715 rdf:first sg:person.0666733253.13
56 rdf:rest Nb91753ceee7c44fea1deba64932ef980
57 Nb91753ceee7c44fea1deba64932ef980 rdf:first sg:person.01160346603.06
58 rdf:rest N98b5417c7ff045eda6fe5a467337a8be
59 Ncf19ea9cc95144ec9038e1e88593edf3 rdf:first sg:person.015226353165.44
60 rdf:rest Na36d2bc907284dc4bdc7c9ebddd60715
61 Ncf986a5653a94c599ee54896aad3403d schema:name nlm_unique_id
62 schema:value 9212404
63 rdf:type schema:PropertyValue
64 Ndc29e15b20484a4dbfc82002b952a6af schema:name doi
65 schema:value 10.1007/s40273-018-0713-7
66 rdf:type schema:PropertyValue
67 Nff7099b094e945e4ad199949fe2a5c95 rdf:first sg:person.0614330503.21
68 rdf:rest Ncf19ea9cc95144ec9038e1e88593edf3
69 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
70 schema:name Medical and Health Sciences
71 rdf:type schema:DefinedTerm
72 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
73 schema:name Public Health and Health Services
74 rdf:type schema:DefinedTerm
75 sg:journal.1102812 schema:issn 1170-7690
76 1179-2027
77 schema:name PharmacoEconomics
78 rdf:type schema:Periodical
79 sg:person.01160346603.06 schema:affiliation https://www.grid.ac/institutes/grid.416266.1
80 schema:familyName Meiklejohn
81 schema:givenName David
82 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01160346603.06
83 rdf:type schema:Person
84 sg:person.013633412165.54 schema:affiliation https://www.grid.ac/institutes/grid.11835.3e
85 schema:familyName Hamilton
86 schema:givenName Jean
87 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013633412165.54
88 rdf:type schema:Person
89 sg:person.014071540030.75 schema:affiliation https://www.grid.ac/institutes/grid.31410.37
90 schema:familyName Morley
91 schema:givenName Nick
92 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014071540030.75
93 rdf:type schema:Person
94 sg:person.015226353165.44 schema:affiliation https://www.grid.ac/institutes/grid.11835.3e
95 schema:familyName Clowes
96 schema:givenName Mark
97 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015226353165.44
98 rdf:type schema:Person
99 sg:person.0614330503.21 schema:affiliation https://www.grid.ac/institutes/grid.11835.3e
100 schema:familyName Pollard
101 schema:givenName Daniel
102 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0614330503.21
103 rdf:type schema:Person
104 sg:person.0666733253.13 schema:affiliation https://www.grid.ac/institutes/grid.11835.3e
105 schema:familyName Kaltenthaler
106 schema:givenName Eva
107 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0666733253.13
108 rdf:type schema:Person
109 sg:person.0670022306.41 schema:affiliation https://www.grid.ac/institutes/grid.11835.3e
110 schema:familyName Tappenden
111 schema:givenName Paul
112 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0670022306.41
113 rdf:type schema:Person
114 sg:person.0730713040.61 schema:affiliation https://www.grid.ac/institutes/grid.11835.3e
115 schema:familyName Simpson
116 schema:givenName Emma
117 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0730713040.61
118 rdf:type schema:Person
119 https://doi.org/10.1016/j.jval.2013.03.690 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021079104
120 rdf:type schema:CreativeWork
121 https://doi.org/10.1016/j.jval.2014.08.2196 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027439758
122 rdf:type schema:CreativeWork
123 https://doi.org/10.1016/s0140-6736(15)00667-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037749972
124 rdf:type schema:CreativeWork
125 https://doi.org/10.1016/s1098-3015(10)74336-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023922575
126 rdf:type schema:CreativeWork
127 https://doi.org/10.1056/nejmoa1306220 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035996659
128 rdf:type schema:CreativeWork
129 https://doi.org/10.1093/annonc/mds643 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037425350
130 rdf:type schema:CreativeWork
131 https://doi.org/10.1111/bjh.12046 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001169896
132 rdf:type schema:CreativeWork
133 https://doi.org/10.1182/blood-2004-04-1323 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019072310
134 rdf:type schema:CreativeWork
135 https://doi.org/10.1200/jco.2008.20.7977 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025441690
136 rdf:type schema:CreativeWork
137 https://www.grid.ac/institutes/grid.11835.3e schema:alternateName University of Sheffield
138 schema:name ScHARR, University of Sheffield, Regent Court, 30 Regent Street, S1 4DA, Sheffield, England, UK
139 rdf:type schema:Organization
140 https://www.grid.ac/institutes/grid.31410.37 schema:alternateName Sheffield Teaching Hospitals NHS Foundation Trust
141 schema:name Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
142 rdf:type schema:Organization
143 https://www.grid.ac/institutes/grid.416266.1 schema:alternateName Ninewells Hospital
144 schema:name Department of Haematology, Ninewells Hospital, Dundee, UK
145 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...